

Revision date: 23-Aug-2011 Version: 3.0 Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Global Manufacturing Pfizer Inc 235 East 42nd Street

235 East 42nd Street New York, NY 10017

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Epirubicin Hydrochloride Injection

Trade Name: Ellence, Farmorubicin; Pharmorubicin

Chemical Family: Anthracycline

Intended Use: Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Appearance: Clear Red Solution

Signal Word: WARNING

Statement of Hazard: Suspected of causing cancer.

Suspected of causing genetic defects.

Additional Hazard Information:

Short Term: Drugs of this class have been associated with rare, but potentially serious cardiac events.

These events have not been observed from occupational exposures, however, those with

preexisting cardiovascular illnesses may be at increased risk from exposure.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on testes,

the developing fetus.

Known Clinical Effects: Adverse effects most commonly reported in clinical use include local irritation, nausea,

vomiting, inflammation of the mouth (stomatitis), facial flushing, conjunctivitis of the eye, tearing

(lachrymation), loss of hair, and discoloration of skin. Effects on blood and blood-forming

organs have also occurred.

EU Indication of danger: Carcinogenic: Category 2

Mutagenic: Category 2

EU Hazard Symbols:



EU Risk Phrases:

R45 - May cause cancer.

R46 - May cause heritable genetic damage. Hazardous Substance. Non-Dangerous Goods.

Australian Hazard Classification

(NOHSC):

Material Name: Epirubicin Hydrochloride Injection Page 2 of 7
Revision date: 23-Aug-2011 Version: 3.0

Nevision date: 25-Aug-2011

2. HAZARDS IDENTIFICATION

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Epirubicin Hydrochloride	56390-09-1	260-145-2	Xn;R22	0.2
			Repr.Cat.2;R60-61	
			Muta.Cat.2;R46	
			Carc.Cat.2;R45	

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Sodium chloride	7647-14-5	231-598-3	Not Listed	*
Water for injection	7732-18-5	231-791-2	Not Listed	*

Additional Information: Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride,

and other chlorine-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Material Name: Epirubicin Hydrochloride Injection Page 3 of 7 Version: 3.0 Revision date: 23-Aug-2011

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Absorb spills with non-combustible absorbent material and transfer into a labeled container for

disposal.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Restrict access to work area. Avoid breathing vapor or mist. Avoid contact with eyes, skin and

> clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA

filtration systems or other equivalent controls.

Store as directed by product packaging. **Storage Conditions:**

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Epirubicin Hydrochloride

Pfizer OEL TWA-8 Hr: $0.6 \, \mu g/m^3$

Sodium chloride

Latvia OEL - TWA 5 mg/m³ Lithuania OEL - TWA 5 mg/m³

Analytical Method: Analytical method available for epirubicin. Contact Pfizer Inc for further information.

Engineering controls should be used as the primary means to control exposures. General **Engineering Controls:**

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended

that all operations be fully enclosed and no air recirculated.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Impervious, disposable gloves (double suggested) are recommended if skin contact with drug Hands:

product is possible and for bulk processing operations.

Wear safety glasses or goggles if eye contact is possible. Eves:

Skin: Impervious disposable protective clothing is recommended if skin contact with drug product is

possible and for bulk processing operations.

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate Respiratory protection:

respirator with a protection factor sufficient to control exposures to below the OEL.

Page 4 of 7

Material Name: Epirubicin Hydrochloride Injection

Revision date: 23-Aug-2011 Version: 3.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:SolutionColor:RedMolecular Formula:MixtureMolecular Weight:Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Epirubicin Hydrochloride

Rat Oral LD 50 1350 mg/kg
Rat Para-periosteal LD50 17 mg/kg
Mouse Oral LD50 > 2000 mg/kg
Mouse Intravenous LD50 31.5 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Epirubicin Hydrochloride

6 Week(s) Rabbit Intravenous 1 mg/kg/day LOAEL Heart, Kidney 6 Week(s) Dog Intravenous 0.4 mg/kg/day LOAEL Kidney

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Epirubicin Hydrochloride

Reproductive & Fertility Rat Oral 0.3 mg/kg/day LOAEL Fertility Reproductive & Fertility Rat Oral 0.1 mg/kg/day NOAEL Fertility

Embryo / Fetal Development Rat Intravenous 0.8 mg/kg/day LOAEL Fetotoxicity

Embryo / Fetal Development Rat Intravenous 2 mg/kg/day LOAEL Teratogenic, Fetotoxicity Embryo / Fetal Development Rat Intravenous 0.2 mg/kg/day NOAEL Teratogenic, Fetotoxicity

PZ00033

Page 5 of 7

Material Name: Epirubicin Hydrochloride Injection

Revision date: 23-Aug-2011 Version: 3.0

11. TOXICOLOGICAL INFORMATION

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Epirubicin Hydrochloride

Bacterial Mutagenicity (Ames) Positive

Mammalian Cell Mutagenicity HGPRT Positive

Chromosome Aberration Human Lymphocytes Positive
Chromosome Aberration Mouse Lymphoma Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Epirubicin Hydrochloride

1 Year(s) Rat Intravenous 3.6 mg/kg LOAEL Tumors, Female reproductive system

18 Month(s) Rat Intravenous 0.5 mg/kg LOAEL Tumors

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol:

EU Indication of danger: Carcinogenic: Category 2

Mutagenic: Category 2

EU Risk Phrases:

R45 - May cause cancer.

R46 - May cause heritable genetic damage.

Page 6 of 7

Material Name: Epirubicin Hydrochloride Injection

Revision date: 23-Aug-2011 Version: 3.0

15. REGULATORY INFORMATION

EU Safety Phrases:

S22 - Do not breathe dust.

S53 - Avoid exposure - obtain special instructions before use. S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:

WARNING

Suspected of causing cancer.

Suspected of causing genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class: D2a very toxic materials



Epirubicin Hydrochloride

EU EINECS/ELINCS List 260-145-2

Sodium chloride

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
231-598-3

Water for injection

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

R45 - May cause cancer.

R46 - May cause heritable genetic damage.

R60 - May impair fertility.

R61 - May cause harm to the unborn child.

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 15 - Regulatory Information.

Page 7 of 7

Material Name: Epirubicin Hydrochloride Injection

Revision date: 23-Aug-2011 Version: 3.0

Prepared by:

Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
